Clinical

Dataset Information

0

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)


ABSTRACT: This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .

DISEASE(S): Ovarian Cancer,Melanoma,Bladder Cancer,Non-small Cell Lung Cancer (nsclc),Solid Tumors,Neoplasms

PROVIDER: 2138571 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2335884 | ecrin-mdr-crc
| 2245745 | ecrin-mdr-crc
2013-07-07 | E-GEOD-39280 | biostudies-arrayexpress
2013-07-07 | E-GEOD-39281 | biostudies-arrayexpress
| 2283030 | ecrin-mdr-crc
2016-07-01 | GSE58624 | GEO
| PRJNA315029 | ENA
| PRJNA315030 | ENA
2013-07-07 | GSE39281 | GEO
2013-07-07 | GSE39280 | GEO